Peter Attia's Longevity Protocol: A Clinical Interpretation

Who Is Peter Attia and Why His Protocol Matters

Peter Attia is a physician who left surgical oncology to build a medical practice focused entirely on extending healthspan and lifespan. His framework, which he calls "Medicine 3.0," treats aging as a modifiable disease process rather than an inevitability, and his public transparency about his own pharmacological and behavioral interventions has made him one of the most closely followed clinicians in the longevity space.

Medical Training and Credibility

Attia completed his surgical residency at Johns Hopkins Hospital and a fellowship in surgical oncology at the National Cancer Institute, part of the National Institutes of Health. He later worked with the applied mathematics team at Johns Hopkins before pivoting to longevity-focused clinical practice. This background in oncology and quantitative analysis shapes his approach: risk-stratified, data-heavy, and oriented toward early intervention years or decades before symptomatic disease.

The "Medicine 3.0" Framework

His core thesis is that conventional medicine (what he labels "Medicine 2.0") waits too long to intervene. By the time a patient presents with a myocardial infarction or a stage III cancer diagnosis, the biological process that caused it has been running for 10 to 30 years. Medicine 3.0 means acting on risk factors in the second or third decade of that timeline, not the last. This is not a fringe position. The European Society of Cardiology's 2021 guidelines on cardiovascular prevention already endorse lifetime risk modeling over short-term risk scores [1].

Rapamycin: The Centerpiece Pharmacological Bet

Attia has spoken extensively on "The Drive" podcast and in interviews about his use of rapamycin (sirolimus) at intermittent, low doses for its potential geroprotective effects. This is the single most controversial element of his protocol because rapamycin is FDA-approved only as an immunosuppressant and anti-rejection agent, not as a longevity drug.

Mechanism and Preclinical Evidence

Rapamycin inhibits mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing kinase that regulates cell growth, autophagy, and protein synthesis. In 2009, the NIA Interventions Testing Program demonstrated that rapamycin extended median lifespan by 9% in male mice and 14% in female mice, even when started at 600 days of age (roughly equivalent to a 60-year-old human) [2]. A 2014 follow-up confirmed the finding across multiple sites and doses [3].

Human Data Gaps

No completed randomized controlled trial has tested rapamycin for lifespan extension in humans. The closest data come from a 2014 study by Mannick et al., published in Science Translational Medicine, which showed that the rapalog everolimus (RAD001) at 0.5 mg daily for 6 weeks improved influenza vaccine response in adults aged 65 and older by approximately 20% [4]. This suggests that low-dose mTOR inhibition may rejuvenate immune function rather than suppress it. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) and AgelessRx's RAPAMYCIN trial are both recruiting or in progress, but neither has reported primary endpoints.

Clinical Risk Assessment

Attia has stated he uses a weekly dosing schedule (typically cited as 5-8 mg once per week, though he has not published his exact current protocol). At immunosuppressive doses (2-5 mg daily), rapamycin carries well-documented risks: hyperlipidemia, impaired wound healing, oral ulcers, and increased infection susceptibility [5]. Whether intermittent low-dose exposure produces the same adverse profile remains unknown. Attia has acknowledged this uncertainty publicly, calling it a "calculated bet" based on the preclinical signal strength.

Lipid Management: Aggressive ApoB Reduction

Attia's position on lipid management is arguably more evidence-based than his rapamycin use, though still more aggressive than standard guideline recommendations. He advocates targeting apolipoprotein B (ApoB) to the 5th percentile or lower, which translates to roughly 60 mg/dL or below.

The ApoB Rationale

ApoB is a single protein carried by every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)). Unlike LDL-C, which measures cholesterol mass, ApoB counts particle number. A 2020 Mendelian randomization analysis published in JAMA Cardiology found that genetically determined lower ApoB levels were associated with reduced cardiovascular events in a log-linear relationship with no apparent lower threshold [6]. Attia frequently cites this and similar analyses to argue that ApoB exposure is cumulative over a lifetime, making early reduction more impactful than late intervention.

Pharmacological Tools

Attia has discussed using statins (rosuvastatin specifically), ezetimibe, and PCSK9 inhibitors. In the FOURIER trial (N=27,564), evolocumab added to statin therapy reduced LDL-C by 59% and lowered the composite cardiovascular endpoint by 15% over a median of 2.2 years [7]. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe to simvastatin reduced LDL-C by an additional 24% and produced a 6.4% relative risk reduction in the primary composite endpoint at 7 years [8].

Where He Diverges from Guidelines

The 2018 ACC/AHA cholesterol guidelines recommend initiating statin therapy based on 10-year ASCVD risk scores, with a treatment threshold typically at 7.5% or higher [9]. Attia's approach ignores short-term risk calculators entirely, instead treating any ApoB above his target as a modifiable exposure. This is a philosophical departure, not a contradiction of the evidence itself. The Mendelian randomization data support the biological plausibility; what is missing is a completed RCT demonstrating that treating low-risk 35-year-olds with statins for 40 years produces net benefit after accounting for adverse effects and cost.

Metformin: Why He Stopped

Attia previously took metformin off-label for its potential anti-aging effects, motivated largely by observational data and the planned TAME (Targeting Aging with Metformin) trial. He has publicly stated he discontinued it. The reason is specific.

The Exercise Interference Signal

A 2019 randomized controlled trial published in Aging Cell (the MASTERS study, N=53) found that metformin blunted the improvements in whole-body insulin sensitivity, VO2 peak, and skeletal muscle mitochondrial respiration that occurred with aerobic exercise training in older adults [10]. The effect was meaningful: the exercise-only group improved VO2 peak by 3 mL/kg/min over 12 weeks, while the metformin-plus-exercise group showed roughly half that gain.

His Stated Reasoning

Attia has explained on multiple podcast episodes that because he prioritizes exercise as his single most powerful longevity intervention, any drug that attenuates exercise adaptation creates a net negative trade-off. He has not ruled out revisiting metformin if TAME trial results (expected to enroll 3,000 participants aged 65-79) show a mortality benefit large enough to offset the exercise blunting [11].

Exercise: The Non-Negotiable Pillar

Attia treats exercise as pharmacology. He has described his weekly protocol in considerable detail across podcast episodes and in Outlive.

Zone 2 Cardio

He prescribes 3 to 4 hours per week of Zone 2 aerobic training (defined as the highest intensity at which lactate remains stable below approximately 2 mmol/L). A 2018 meta-analysis in Mayo Clinic Proceedings (N=122,007) found that cardiorespiratory fitness, measured by VO2 max, was inversely associated with all-cause mortality, with no upper threshold of benefit. Individuals in the top quartile of fitness had 80% lower mortality compared to the bottom quartile [12].

Strength and Stability

He programs 3 to 4 strength training sessions per week, with an emphasis on grip strength, hip hinge movements, and functional stability. Grip strength alone has been shown to predict cardiovascular mortality independently of blood pressure in a Lancet study of 139,691 adults across 17 countries [13]. Attia frames stability training (balance, proprioception, spinal control) as "insurance against the fall that kills you at 85."

VO2 Max as a Biomarker

Attia has repeatedly identified VO2 max as the single strongest predictor of all-cause mortality, citing the 2018 JAMA Network Open study by Mandsager et al. [12]. His stated personal target is a VO2 max that places him in the top 2% for his age decade, which he aims to maintain into his 60s and 70s.

Hormone Optimization and Testosterone

Attia has discussed testosterone replacement therapy (TRT) in the context of male hormonal decline, though he is less specific about his own use than about rapamycin or lipid pharmacology.

Clinical Context

The Endocrine Society's 2018 guidelines recommend testosterone therapy for men with symptomatic hypogonadism and consistently low morning total testosterone (below 300 ng/dL on at least two measurements) [14]. The TRAVERSE trial (N=5,246), published in The New England Journal of Medicine in 2023, found that testosterone replacement in men aged 45-80 with hypogonadism and cardiovascular risk factors did not increase the incidence of major adverse cardiovascular events over a mean of 33 months, resolving a longstanding safety concern [15].

Attia's Perspective

Attia has stated that he views testosterone optimization as part of a broader endocrine management strategy, not an isolated intervention. He has emphasized the importance of monitoring hematocrit, PSA, and estradiol during TRT, consistent with Endocrine Society recommendations [14].

Continuous Glucose Monitoring and Metabolic Health

Attia was an early advocate for CGM use in non-diabetic individuals. He has worn a continuous glucose monitor for years and has shared data on glucose variability, postprandial spikes, and the relationship between glucose dysregulation and chronic disease.

Evidence for CGM in Non-Diabetics

A 2023 study in The Lancet Regional Health found that glucose variability (measured by CGM) in non-diabetic adults was associated with increased carotid intima-media thickness, a surrogate marker for atherosclerosis [16]. The clinical utility of CGM in healthy populations remains debated. The American Diabetes Association does not recommend routine CGM for individuals without diabetes or prediabetes, though Attia argues the data support using it as a behavioral feedback tool to optimize dietary choices and meal timing.

Supplements and Micronutrients

Attia has discussed several supplements on "The Drive," though he treats them as lower-priority than exercise, sleep, and pharmacological interventions.

Documented Supplements

He has mentioned taking omega-3 fatty acids (EPA/DHA at high doses, typically 2-4 g/day of combined EPA and DHA), vitamin D (targeting serum 25-hydroxyvitamin D levels of 40-60 ng/mL), magnesium (specifically magnesium L-threonate for potential CNS effects and other forms for general repletion), and methylfolate. The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl (a purified EPA formulation) at 4 g daily reduced major cardiovascular events by 25% versus placebo in statin-treated patients with elevated triglycerides [17]. Whether over-the-counter fish oil produces equivalent benefit is unresolved.

What He Does Not Take

Attia has been publicly skeptical of most "anti-aging" supplements, including resveratrol and NAD+ precursors (NMN, NR), citing insufficient human data. He has stated that he does not take either as of his most recent public comments.

Sleep: The Underappreciated Variable

Attia dedicates significant attention to sleep optimization, calling it "the best performance-enhancing drug." He targets 8 hours of sleep per night, tracks sleep architecture, and has discussed using pharmacological aids (including trazodone at low doses) for periods of disrupted sleep.

A 2022 study in the Journal of the American College of Cardiology (N=172,321) found that adults aged 40-79 who met five low-risk sleep behaviors (adequate duration, regularity, no insomnia, no snoring, no daytime sleepiness) had 30% lower all-cause mortality and 21% lower cardiovascular mortality over a median follow-up of 4.3 years [18].

What Is Missing from the Evidence Base

The most honest clinical interpretation of Attia's protocol is that each individual component has supporting evidence of varying strength, but no trial has tested the combination. The exercise and lipid management components rest on the most strong evidence. Rapamycin for human longevity remains preclinical. Metformin for aging awaits TAME trial results. His approach is a physician's informed bet, not a validated protocol, and he has said as much. Patients should not replicate any pharmacological element without physician supervision and individualized risk assessment. The starting point for anyone considering a longevity-oriented medical strategy is a comprehensive metabolic and cardiovascular evaluation with a clinician experienced in preventive medicine, including ApoB measurement, VO2 max testing, DEXA body composition, and cancer screening aligned with personal and family risk.